≡ Risteys
R13

Documentation Changelog GitHub Contact & Feedback
info icon

Malignant neoplasm of pyriform sinus, including Hilmo

Endpoint Browser

C3_PIRIFORMSINUS_WIDE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519972

1. Apply sex-specific rule

None

519972

2. Check conditions

None

519972

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — C12&
  • Hospital discharge: ICD-9 — 1481A
  • Hospital discharge: ICD-8 — 1481
  • Cause of death: ICD-10 — C12&
  • Cause of death: ICD-9 — 1481A
  • Cause of death: ICD-8 — 1481
  • Cancer registry: Topography ICD-O-3 — C12
  • Cancer registry: Morphology ICD-O-3 — ANY
  • Cancer registry: Behaviour codes — 3

3 out of 7 registries used, show all original rules.

50

4. Check minimum number of events

None

50

5. Include endpoints

None

50

6. Filter based on genotype QC (FinnGen only)

49

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

First used in FinnGen datafreeze
DF12

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 49 6 43
Unadjusted period prevalence (%) 0.02 0.00 0.02
Median age at first event (years) 67.52 59.06 68.70

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
50
Matched controls
500
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C12
ICD-10 Finland
Malignant neoplasm of piriform sinus
+∞
56.3
43
*
130
Kela drug reimbursment
Malignant tumour
+∞
37.2
31
*
WF002
NOMESCO Finland
Radical radiotherapy
+∞
26.4
23
*
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
444.9
26.3
24
*
JDB10
NOMESCO Finland
Percutaneous gastrostomy
444.9
26.3
24
*
UJC01
NOMESCO Finland
Scopy of lower throat
103.0
22.2
23
*
8070/3-C12.9
ICD-O-3
Squamous cell carcinoma, NOS, of pyriform sinus
+∞
17.7
16
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
17.7
16
*
A03FA01
ATC
metoclopramide; systemic, rectal
20.3
16.9
27
27
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
189.4
14.2
14
*
GDA98
NOMESCO Finland
Other bronchoscopic incision, excision of lesion or repair of lung
94.7
13.4
14
*
C13.9
ICD-10 Finland
Malignant neoplasm: Hypopharynx, unspecified
+∞
13.1
12
*
XX3DW
NOMESCO Finland
Time consuming IT work
32.6
12.5
16
7
UJC02
NOMESCO Finland
Rigid oesophagoscopy
85.6
12.3
13
*
N02AA05
ATC
oxycodone; systemic
8.4
12.1
22
43
WZC00
NOMESCO Finland
Treatment plan or consultation
7.6
11.8
28
72
H02AB02
ATC
dexamethasone; systemic
77.0
11.2
12
*
WZC30
NOMESCO Finland
Teaching
12.6
11.1
21
27
A04AA01
ATC
ondansetron; systemic, rectal
51.3
10.5
12
*
D10.7
ICD-10 Finland
Benign neoplasm: Hypopharynx
+∞
9.7
9
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
+∞
9.7
9
*
UDH02
NOMESCO Finland
Rhinopharyngoscopy
18.8
9.4
14
10
A06AD11
ATC
lactulose; oral
6.5
8.8
19
43
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
107.4
8.7
9
*
JCA55
NOMESCO Finland
Endoscopic dilatation of oesophagus
+∞
8.6
8
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
8.6
8
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
22.9
8.0
11
6
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
53.7
8.0
9
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
7.5
7
*
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
+∞
7.5
7
*
C77.0
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph nodes of head, face and neck
+∞
7.5
7
*
8070/3-C13.9
ICD-O-3
Squamous cell carcinoma, NOS, of hypopharynx, NOS
+∞
7.5
7
*
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
4.7
6.8
29
114
EBA15
NOMESCO Finland
Extraction of multiple teeth
17.4
6.7
10
7
UDQ22
NOMESCO Finland
Microlaryngoscopy
79.6
6.6
7
*
UDQ12
NOMESCO Finland
Flexible laryngoscopy
10.9
6.5
12
14
R4190
NOMESCO Finland
Nutritional therapy
31.0
6.4
8
*
8070/3-C32.9
ICD-O-3
Squamous cell carcinoma, NOS, of larynx, NOS
+∞
6.4
6
*
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
+∞
6.4
6
*
L01BC06
ATC
capecitabine; oral
+∞
6.4
6
*
C13.1
ICD-10 Finland
Malignant neoplasm: Aryepiglottic fold, hypopharyngeal aspect
+∞
6.4
6
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
6.4
6
*
D14.1
ICD-10 Finland
Benign neoplasm: Larynx
+∞
6.4
6
*
C13.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of hypopharynx
+∞
6.4
6
*
JN4BD
NOMESCO Finland
Extensive body CT
11.4
6.2
11
12

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
19
15
19.55
12.47
1.7
1.1
—
—
—
0
0
30
100
6.00
9.17
4.0
2.0
—
—
—
0
0
17
26
9.32
8.00
2.7
2.5
0.19
0.19
g/l
0.04
17
19
26
97
4.50
6.46
3.6
1.5
—
—
—
0
0
29
141
3.52
4.55
7.9
3.9
33.38
34.82
g/l
0.64
29
132
22
96
3.31
4.00
4.3
3.5
—
—
—
0
0
34
203
3.11
3.47
26.1
15.1
1.36
1.42
inr
—
10
39
9
22
4.75
3.05
4.7
3.0
—
—
—
0
0
12
43
3.36
2.88
6.0
7.4
102.67
104.77
mmol/l
0.57
12
43
15
62
3.03
2.87
6.4
2.2
2.47
2.44
mmol/l
0.71
15
57
9
24
4.33
2.83
1.8
1.1
—
—
—
0
0
28
165
2.58
2.70
5.5
4.8
0.04
0.04
e9/l
0.22
22
137
33
218
2.51
2.40
7.5
4.6
6.91
7.08
mmol/l
0.16
33
204
17
83
2.59
2.36
1.4
1.2
—
—
—
0
0
13
55
2.84
2.36
2.7
2.5
12.02
12.25
umol/l
0.05
13
50
27
165
2.38
2.31
5.6
4.8
0.65
0.62
e9/l
0.22
22
136
28
177
2.32
2.18
5.7
4.6
0.17
0.22
e9/l
1.24
23
145
16
79
2.51
2.15
2.0
1.9
3.72
2.81
mg/l
0.66
11
65
8
28
3.20
1.96
10.6
9.5
—
—
—
0
0
6
141
0.35
1.93
4.5
3.3
—
—
—
0
0
9
36
2.82
1.85
10.8
3.2
—
—
—
0
0
8
30
2.98
1.81
9.7
7.6
0.82
1.77
mmol/l
—
8
30
11
49
2.60
1.79
2.8
2.4
19.43
22.36
%
0.39
11
44
10
44
2.58
1.68
2.2
1.8
1.57
1.59
%
—
10
37
24
156
2.04
1.62
6.4
4.9
—
—
—
0
0
17
97
2.14
1.61
3.3
3.3
7.41
7.39
ph
—
5
11
9
37
2.74
1.58
1.9
2.2
—
—
—
0
0
33
243
2.05
1.55
3.9
3.5
—
—
—
0
0
23
153
1.93
1.41
2.1
2.0
83.94
89.82
pmol/l
0.26
16
90
12
63
2.19
1.37
8.9
4.7
—
—
—
0
0
8
36
2.45
1.31
2.5
3.4
2.59
1.71
mmol/l
—
8
30
18
113
1.93
1.29
6.3
3.6
—
—
—
0
0
0
30
0.00
1.01
0.0
1.5
—
—
—
0
0
6
27
2.38
0.97
1.5
1.6
—
—
—
0
0
14
91
1.75
0.87
2.9
2.2
—
—
—
0
0
6
32
1.99
0.85
4.7
2.1
8.50
8.06
umol/l
—
6
27
20
147
1.60
0.79
11.3
6.8
0.00
0.00
e9/l
0.50
15
112
13
85
1.72
0.79
2.5
2.9
—
—
—
0
0
9
56
1.74
0.78
1.8
1.5
—
—
—
0
0
11
69
1.76
0.76
2.1
1.9
2.70
2.84
e6/l
0.05
11
59
5
30
1.74
0.63
1.6
1.3
—
—
—
0
0
0
19
0.00
0.62
0.0
1.4
—
—
—
0
0
13
91
1.58
0.60
3.5
2.8
—
—
—
0
0
33
373
0.66
0.60
3.4
4.1
1.10
1.28
mmol/l
1.11
28
335
34
382
0.66
0.60
3.7
4.7
3.99
4.35
mmol/l
1.03
29
352
6
37
1.70
0.58
3.2
1.9
67.75
63.99
e9/l
—
6
29
34
381
0.66
0.58
3.7
4.6
1.40
1.35
mmol/l
0.22
28
345
16
120
1.49
0.55
1.9
2.2
77.56
293.95
u/l
3.32
16
111
7
49
1.50
0.48
1.1
1.6
—
—
—
0
0
5
32
1.62
0.43
1.2
3.2
64.14
65.36
g/l
—
5
27
11
81
1.46
0.40
6.9
3.1
32.09
241.13
ng/l
1.77
11
68
16
128
1.37
0.38
1.6
3.2
—
5.88
—
0
13
36
390
0.73
0.37
4.3
5.3
2.17
2.56
mmol/l
1.69
29
354
6
43
1.45
0.36
1.5
2.7
6.68
12.17
ug/l
—
6
36
35
375
0.78
0.26
5.2
4.9
5.99
6.27
mmol/l
0.92
30
329
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
630.60
—
0
10
0
10
0.00
0.21
0.0
1.1
—
156.51
—
0
10
6
47
1.31
0.21
1.8
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
26
278
0.87
0.13
5.0
4.0
—
—
—
0
0
19
173
1.16
0.13
3.4
3.5
18.86
69.18
ng/l
1.83
14
130
6
70
0.84
0.08
1.5
3.5
—
1.02
—
0
7
8
76
1.06
0.08
1.6
3.2
—
—
—
0
0
40
410
0.88
0.06
43.4
18.0
31.07
30.74
pg
0.46
40
400
40
410
0.88
0.06
44.2
18.2
126.90
139.59
g/l
4.22
40
401
40
409
0.89
0.04
43.8
18.2
225.28
230.94
e9/l
0.26
40
392
40
409
0.89
0.04
43.5
18.1
92.69
91.87
fl
0.42
40
399
40
392
1.10
0.03
37.4
15.7
137.88
139.73
mmol/l
2.61
40
378
36
368
0.92
0.03
5.8
6.8
39.60
41.43
mmol/mol
0.64
30
335
39
383
1.08
0.02
25.5
12.1
—
—
—
0
0
26
267
0.95
0.01
5.9
3.7
5.26
2.02
ug/l
0.52
26
240
40
396
1.05
0.00
37.2
14.8
88.67
87.53
umol/l
0.04
40
396
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
34.40
—
0
5
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
62.80
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
0.25
—
0
7
0
9
0.00
-0.00
0.0
1.7
—
4.17
—
0
9
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
0.92
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: C3_PIRIFORMSINUS_WIDE – Malignant neoplasm of pyriform sinus, including Hilmo

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).